Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

401
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
401
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

502
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
502
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

468
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
468
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

453
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
453

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alterations of right ventricular assessment by use of an ultrasound-enhancing agent during routine visualization of the left ventricle.

European heart journal. Imaging methods and practice·2026
Same author

Multimodality imaging of patent ductus arteriosus with severe pulmonary hypertension following 3 pregnancies.

Radiology case reports·2026
Same author

Bioinformatics and AI/ML approaches using multi-omics data to accelerate diagnosis and delivery of precision care for patients with rare diseases.

Methods in cell biology·2026
Same author

A Case Series of Trileaflet Mitral Valves.

CASE (Philadelphia, Pa.)·2026
Same author

Cardiovascular Computed Tomography Angiographic Assessment of Simple Cardiac Shunts in Adults.

Reviews in cardiovascular medicine·2025
Same author

Strategic Approach Towards the Evaluation of HeartMate 3 Left Ventricular Assist Devices Using Multimodality Imaging.

The American journal of cardiology·2025

Related Experiment Video

Updated: Jan 15, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.2K

Hypertrophic Cardiomyopathy: Current Perspectives.

Dhruvil Patel1, Ruchika Bhargav1, Aliaa Mousa1

  • 1Department of Cardiology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA.

Reviews in Cardiovascular Medicine
|October 15, 2025
PubMed
Summary

Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting 1 in 200-500 people. This review explores its genetic basis, diagnosis via imaging, and novel therapies beyond traditional treatments.

Keywords:
aficamtenalcohol septal ablationhypertrophic cardiomyopathymavacamtensudden cardiac deathsurgical myectomy

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.2K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.6K

Area of Science:

  • Cardiology
  • Genetics
  • Pathophysiology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing left ventricular hypertrophy (LVH).
  • Prevalence estimates range from 1 in 200 to 1 in 500 individuals.
  • Ongoing research identifies new mutations and pathophysiological mechanisms.

Purpose of the Study:

  • To systematically review the genetic and pathophysiological basis of HCM.
  • To explore the role of multimodality imaging in diagnosing and risk-stratifying HCM patients.
  • To examine contemporary management strategies and novel therapies for HCM.

Main Methods:

  • Literature review of genetic and pathophysiological studies on HCM.
  • Analysis of multimodality imaging techniques for HCM diagnosis and risk stratification.
  • Examination of current and emerging therapeutic strategies for HCM.

Main Results:

  • Numerous pathogenic mutations linked to HCM have been identified.
  • Multimodality imaging is crucial for accurate diagnosis and risk stratification.
  • Novel therapies targeting molecular mechanisms offer new treatment avenues.

Conclusions:

  • HCM understanding has evolved, leading to refined definitions and recognition.
  • Advanced imaging and genetic insights improve patient management.
  • Emerging targeted therapies provide alternatives to traditional interventions like myectomy or septal ablation.